For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Anaplastic Large Cell Lymphoma

Clinical Trial Title: 
A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117.
Clinical Trial Protocol ID: 
14032802-CAOI
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy and to determine the tolerability of crizotinib given in combination with chemotherapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less than 22 years of age at the time of study enrollment.
  • Have been newly diagnosed with histologically proven ALCL.
  • Have CD30 positive disease.
  • Have ALK positive disease (defined by local institutional standards).
  • Have stage II, Ill, or IV disease.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane